Click HERE to download the PDF version

Ben Potenza, VP Marketing at asset management specialist EquipNet, discusses how pharmaceutical, biotechnology and chemical companies can maximise their return on investment in laboratory equipment. He shares a case study of how a pioneering whole-business approach helped a leading global healthcare provider following a complete site closure, involving asset redeployment and the sale of surplus laboratory and production equipment.

Millions are spent every year on the laboratory equipment and instrumentation that is essential for the daily work of research and analysis in the pharmaceutical, biotechnology and chemical sectors. Yet research suggests that a significant amount of ‘lab assets’ are laying idle. Industry surveys suggest that on average, 5% of a manufacturing company’s global asset base is lying idle at any one time, as projects are completed, or the empha ...